Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy
Luzhou Xua,
Lei Zhua,
Kai Zhenga,
Junlou Liub,
Panpan Tianc,
Di Hub,
Qianqian Wangb,
Qiaoyun Zuob,
Xiaosong Ouyangb,
Yanna Daib,
Yuxian Fub,
Xinyi Daib,
Fang Huang*d and
Jun Cheng*ef
aGastroenterology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China
bThe First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, 210023, China
cInternal Medicine Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China
dSchool of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, 211199, China. E-mail: chengtianle007@163.com
eJiangsu Hongdian Research Institute of Traditional Chinese Medicine Industry, Nanjing, 210042, China. E-mail: cj9119@sina.com
fNanjing Zhongshan Pharmaceutical Co. Ltd, Nanjing, 210046, China
First published on 8th May 2025
Abstract
Correction for ‘The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy’ by Luzhou Xu et al., J. Mater. Chem. B, 2021, 9, 3068–3078, https://doi.org/10.1039/D1TB00127B.
The authors regret an error in the names of the cell lines used in this study. Specifically, the human gastric cancer cell lines employed were BGC 823 and SGC 7901, both procured from Shanghai Fuheng Biotechnology Co., Ltd.
However, the name BGC 823 was incorrectly spelled as MGC 823 in the “Cellular uptake” section, the “Cellular uptake studies” section, and the caption of Fig. 4. Additionally, in the “Cell and animals” section of the supporting information, BGC 823 was erroneously recorded as MGC 803.
The results of Short Tandem Repeat (STR) analysis conducted by the National Collection of Authenticated Cell Cultures (Shanghai, China) and Jiangsu KeyGen Biotechnology Co., Ltd (Nanjing, China) confirmed that the submitted BGC 823 cells precisely correspond to the human gastric cancer BGC 823 cells as documented in the ExPASy database.
The caption of Fig. 3 was incorrect as it referred to panel C twice, and should have read:
Fig. 3 Redox-responsive evaluation of the P-ss-ORI and P-ORI formulations. (A)–(C) Size changes of P-ss-ORI and P-ORI after incubation at pH 7.4 (A), pH 7.4 with 10.0 mM GSH (B), or pH 5.0 (C), n = 3. (D and E) Cumulative release of ORI from P-ORI (D) or P-ss-ORI (E) in the presence of 10.0 mM or 20.0 μM GSH, pH 7.4, and pH 5.0, respectively, n = 3.
In Fig. 4, the fluorescein used in the cell uptake is FITC, which was incorrectly labelled as Coumarin-6.
The caption of Fig. 5 was incorrect due to incorrect labelling of panels B and C, the corrected caption is shown below:
Fig. 5 In vitro cytotoxicity of GC cell lines following treatment with PPM preparations. (A and C) Cell viability of BGC 823 cells after incubation with PEG-b-PLL-DTPA, PEG-b-PLL-SA, ORI, P-ss-ORI, or P-ORI (n = 6). (B and D) Cell viability of SGC 7901 cells after culturing with PEG-b-PLL-DTPA, PEG-b-PLL-SA, ORI, P-ss-ORI, or P-ORI (n = 6).
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2025 |